

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of the claims in the application:

1. (Cancelled)

2. (Currently Amended) A method for treating a disorder, disease or condition benefiting from an increase in mitochondrial respiration; wherein the disorder, disease or condition is selected from the group consisting of obesity, ~~atherosclerosis, hypertension,~~ diabetes, and type 2-diabetes, impaired glucose tolerance, dyslipidemia, coronary heart disease, gallbladder-disease, osteoarthritis, endometrial cancer, breast cancer, prostate cancer, and colon-cancer, comprising administering to a patient in need thereof a therapeutically effective amount of a compound having a slope calculated from the equation

$$X^n = (Y_2 - Y_0) / (Y_1 - Y_0)$$

wherein

Y_0 is the degree of stimulation measured as counts per minute (cpm) of radioactivity in control samples without added test compound,

and

Y_1 is the degree of stimulation measured as cpm of radioactivity with added test compound in a concentration of $EC_{50}/2$,

Y_2 is the degree of stimulation measured as cpm of radioactivity with added test compound in concentration of $2 \times EC_{50}$, and

X is 2,

or


Y_1 is the degree of stimulation measured as cpm of radioactivity with added test compound in a concentration of $EC_{50}/3$,

Y_2 is the degree of stimulation measured as cpm of radioactivity with added test compound in concentration of $3 \times EC_{50}$, and

X is 3,

and

n is the slope,
wherein,
the value of the slope n calculated for the compound is less than the value of the slope n calculated for carbonylcyanide *p*-trifluoromethoxy-phenylhydrazone as test compound;
and wherein the compound is of formula (III)



(III)

wherein

R^6 is halogen, -CHO, -CO₂R⁴³, -COR⁴³, -SO₃H, -CCl₃, -CF₃, -CN, -CH=CH-R⁴⁴, -C(R⁴⁴)(R⁴⁵), -SOR⁴³, -SO₂R⁴³ or aryl substituted with from one to five substituents selected from halogen, -CHO, -CO₂R⁴³, -COR⁴³, -SO₃H, -CCl₃, -CF₃, -NO, -NO₂, -CN, -CH=CH-R⁴⁴, -CH(R⁴⁴)(R⁴⁵), -SOR⁴³, or -SO₂R⁴³, wherein

R⁴³ is hydrogen or alkyl; and

R⁴⁴ and R⁴⁵ independently of each other are halogen, -CHO, -CO₂R⁴⁶, -COR⁴⁶, -SO₃H, -CCl₃, -CF₃, -NO, -NO₂, -CN, -SOR⁴⁶, -SO₂R⁴⁶, wherein


R⁴⁶ is hydrogen, alkyl, or aryl;

R⁷ is alkyl, nitro, halogen, alkyl-O-, alkyl-C(O)-, or alkyl-C(O)-O-; and

R⁸ and R⁹ independently of each other are hydrogen, alkyl, nitro, halogen, alkyl-O-, alkyl-C(O)-, alkyl-C(O)-O-, or aryl;

or

R⁷ and R⁸ together form one of the diradicals



wherein R⁴⁷ and R⁴⁸, independently of each other, are hydrogen, alkyl, nitro, halogen, alkyl-O-, alkyl-C(O)-, or alkyl-C(O)-O-,

wherein the two valence atoms in the diradical are attached to adjacent carbon atoms in the phenyl ring; and

R⁹ is hydrogen, alkyl, nitro, halogen, alkyl-O-, or alkyl-C(O)-;

or a pharmaceutically acceptable salt, or solvate thereof.

3. (Cancelled)

4. (Cancelled)

5. (Previously presented) A method according to claim 2, wherein the condition is obesity.

6. (Previously presented) A method according to claim 2, wherein the disease is type 2 diabetes.

7. (Original) A method according to claim 6, wherein the patient in need thereof is obese.

8-13. (Cancelled)

14. (Previously presented) A method according to claim 2, wherein the compound is a chemical uncoupler.

15. (Previously presented) A method according to claim 2, wherein the compound is a cation.

16. (Cancelled)

17. (Previously presented) A method according to claim 2, wherein the compound is 4-hydroxy-3-nitroacetophenone.

18-49. (Cancelled)